Searched for
PARAS BRANDS
Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- Innocent Fresh plans expansion across 40-50 citiesThe company partners with rural women for preparation. Their products are available in retail and online. Future growth includes e-commerce...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsIf the US-Iran ceasefire holds, the markets may see some recovery. The movement of crude oil prices and its impact on the markets supports ...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the latest news flow from the Gulf region, the probability is high that we might once again see the bulls attempting a comeback. As u...
- Trading platform Trackk raises $3.7 million led by Lightspeed VenturesTrackk, a stock trading platform for Gen Z investors, has secured $3.7 million in a funding round. Lightspeed Ventures led the investment. ...
- ET Women Conclave 2026 spotlights leadership, reinvention, and powerful conversationsThe ET Women Conclave 2026 celebrated inspiring leaders, entrepreneurs, and changemakers with dialogues on authenticity, wellness, and impa...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Flexible workspace firms clinch big deals in Q4Flexible workspace operators secured major office deals in the March quarter. Smartworks and WeWork led with substantial space leases acros...
- Everstone leads $150 million infusion in SaaS firm WingifySoftware firm Wingify secured Rs 1,381 crore in a new funding round led by Everstone Capital. This investment follows Wingify's recent anno...
- Paras ex-promoters return to offer more personal care productsDevendra Patel has launched Layer’r brand of perfumes and deodorants, following the footprints of his brother, Darshan, who launched Vini C...
- Former Paras co-promoter launches personal care brand Layer'rFormer Paras Pharma co-promoter Devendra Patel is back in the Rs 30,000 cr personal care market with his new brand Layer’r.
- Paras fought a dozen copyright cases every yearSince the days of its first successful product Stopache in the ‘80s, Paras Pharmaceuticals has seen copycats aping its flagship brands.
- Reckitt Benckiser to buy Paras Pharmaceuticals for Rs 3,260 croreBritish consumer goods firm Reckitt Benckiser Group, confirmed it will buy Ahmedabad-based Paras Pharmaceuticals for 3,260 crore ($726 mill...
- The Paras brands we’re acquiring are complementary to our portfolio: Chander Mohan Sethi, Reckitt Benckiser IndiaReckitt Benckiser, maker of Dettol soaps, Harpic toilet cleaner and Vanish stain remover, outdid a number of contenders including Emami to ...
- Darshan Patel targets Paras Pharmaceuticals brandsDarshan Patel, the estranged brother of Paras Pharmaceuticals CMD Girish Patel, is set to take on brands such as DermiCool, ItchGuard and B...
- Brand power may steer Paras deal at high valuationParas Pharmaceuticals look for suitors seeking Rs 3,500 crore, thus valuing the OTC major eight times its turnover.
- Sequoia invests $12 mn in Paras PharmaLeading venture capital and growth equity investor Sequoia Capital India has invested $12 million in Ahmedabad-based over-the-counter (OTC)...
Load More
